Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Cet article passe en revue les données concernant l'efficacité et la sécurité des agents immunothérapeutiques pour traiter un cancer du sein de stade précoce
Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have modest clinical activity in advanced breast cancer, there is a growing interest in combinatorial modalities and particularly for their rapid development in the early disease setting. The plethora of ongoing immunotherapy trials in early breast cancer comes at a time when solid data in advanced disease are still imperfect. This review offers a perspective on the efforts to establish the efficacy and safety of immunotherapeutic agents in early breast cancer.
Annals of Oncology , résumé, 2020